文献速递胸部肿瘤

辅助奥希替尼治疗已切除的EGFR突变IB-IIIA期非小细胞肺癌:III期随机ADAURA试验的更新结果

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
PubMed 文献 · J Clin Oncol · 2023-01-31

ADAURA试验更新分析显示,在完全切除的EGFR突变IB-IIIA期NSCLC中,辅助奥希替尼较安慰剂显著延长无病生存期(DFS),II-IIIA期4年DFS率70%对29%,总人群73%对38%,并降低局部和远处复发风险、改善中枢神经系统DFS,安全性一致。

要点

  • II-IIIA期DFS HR 0.23(95%CI 0.18-0.30),4年DFS率奥希替尼70%对安慰剂29%。
  • 总人群DFS HR 0.27(95%CI 0.21-0.34),4年DFS率奥希替尼73%对安慰剂38%。
  • II-IIIA期中枢神经系统DFS HR 0.24(95%CI 0.14-0.42),安全性特征与主要分析一致。

核心结论

  • 更新数据表明辅助奥希替尼较安慰剂延长DFS、降低局部和远处复发风险、改善中枢神经系统DFS且安全性特征一致,支持辅助奥希替尼在已切除EGFR突变NSCLC中的疗效。

研究设计与样本

  • III期随机、双盲、安慰剂对照ADAURA试验(NCT02511106),682例完全切除的EGFR突变(外显子19缺失/L858R)IB-IIIA期NSCLC患者按1:1随机接受奥希替尼80 mg每日一次或安慰剂治疗3年。
  • 主要终点为研究者评估的II-IIIA期DFS,采用分层log-rank检验;在DFS统计学显著性提前报告后,未计划进一步正式统计学检验。

主要发现

  • 数据截止2022年4月11日,II-IIIA期奥希替尼组中位随访44.2个月、安慰剂组19.6个月,DFS HR 0.23(95%CI 0.18-0.30),4年DFS率奥希替尼组70%对安慰剂组29%。
  • 总人群DFS HR 0.27(95%CI 0.21-0.34),4年DFS率奥希替尼组73%对安慰剂组38%。
  • 奥希替尼组局部/区域复发和远处复发的患者数少于安慰剂组,II-IIIA期中枢神经系统DFS HR 0.24(95%CI 0.14-0.42)。
  • 奥希替尼长期安全性特征与主要分析一致。

局限性

  • 在DFS统计学显著性提前报告后,未计划进一步正式统计学检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data. METHODS: Overall, 682 patients with stage IB-IIIA (American Joint Committee on Cancer/Union for International Cancer Control, seventh edition) EGFR-mutated (exon 19 deletion/L858R) NSCLC were randomly assigned 1:1 (stratified by stage, mutational status, and race) to receive osimertinib 80 mg once-daily or placebo for 3 years. The primary end point was DFS by investigator assessment in stage II-IIIA disease analyzed by stratified log-rank test; following early reporting of statistical significance in DFS, no further formal statistical testing was planned. Secondary end points included DFS in stage IB-IIIA, overall survival, and safety. Patterns of recurrence and CNS DFS were prespecified exploratory end points. RESULTS: At data cutoff (April 11, 2022), in stage II-IIIA disease, median follow-up was 44.2 months (osimertinib) and 19.6 months (placebo); the DFS HR was 0.23 (95% CI, 0.18 to 0.30); 4-year DFS rate was 70% (osimertinib) and 29% (placebo). In the overall population, DFS HR was 0.27 (95% CI, 0.21 to 0.34); 4-year DFS rate was 73% (osimertinib) and 38% (placebo). Fewer patients treated with osimertinib had local/regional and distant recurrence versus placebo. CNS DFS HR in stage II-IIIA was 0.24 (95% CI, 0.14 to 0.42). The long-term safety profile of osimertinib was consistent with the primary analysis. CONCLUSION: These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023. PMID: 36720083. doi:10.1200/JCO.22.02186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。